Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.
暂无分享,去创建一个
J. Benítez | M. Piris | M. Sánchez-Beato | B. Martínez-Delgado | M. Mateo | J. Martínez | L. Sánchez-Verde | P. Martínez | A. Sáez | R. Villuendas | J. García | J. Martinez | J. Martinez | J. Martinez | J. García | P. Martı́nez | Juan C. Martinez | Juan F. García | Javier Benitez | Juan F. García
[1] M. Ng,et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.
[2] J. Benítez,et al. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin’s lymphoma , 1997, Leukemia.
[3] J. Herman,et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.
[4] J. Geradts,et al. High frequency of aberrant p16(INK4A) expression in human breast cancer. , 1996, The American journal of pathology.
[5] C. Cordon-Cardo,et al. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. , 1996, The American journal of pathology.
[6] F. Sigaux,et al. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.
[7] F. Kaye,et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. , 1995, Journal of the National Cancer Institute.
[8] R. Kratzke,et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.
[9] Kathleen R. Cho,et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.
[10] R. Siebert,et al. Homozygous loss of the MTSl/pl6 and MTS2/pl5 genes in lymphoma and lymphoblastic leukaemia cell lines , 1995, British journal of haematology.
[11] T. Kinoshita,et al. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. , 1995, Blood.
[12] O. Olopade,et al. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. , 1995, Blood.
[13] S. Ogawa,et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. , 1995, Blood.
[14] H. Koeffler,et al. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. , 1995, Blood.
[15] Y. Hayashi,et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.
[16] C. D. Edwards,et al. A novel p16INK4A transcript. , 1995, Cancer research.
[17] J. Herman,et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.
[18] F. Haluska,et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.
[19] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[20] W Arap,et al. Loss of P16INK4 expression is frequent in high grade gliomas. , 1995, Cancer research.
[21] M. Piris,et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Yuille,et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.
[23] R. Ueda,et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. , 1995, Cancer research.
[24] R. DePinho,et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.
[25] G. Finocchiaro,et al. Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.
[26] M. Pagano,et al. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. , 1994, Cancer research.
[27] I. Herskowitz,et al. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle , 1994, Cell.
[28] K. Tanaka,et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. , 1994, Blood.
[29] Gregory J. Hannon,et al. pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.
[30] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[31] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[32] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[33] D. Carson,et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.
[34] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[35] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[36] J. Kirkwood,et al. Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[37] T. Sekiya,et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.
[38] E. Campo,et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.
[39] Y. Xiong,et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. , 1995, Blood.
[40] G. Hannon,et al. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.
[41] M. Borrello,et al. Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. , 1992, Cytometry.